| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | MOVE LOGISTICS GROUP LIMITED: Annual Report to shareholders | - | ASX | ||
| 15.09. | SUMMERSET GROUP HOLDINGS LIMITED: Update - Dividend/Distribution - SNZ | - | ASX | ||
| 15.09. | MERIDIAN ENERGY LIMITED: Update - Dividend/Distribution - MEZ | - | ASX | ||
| 15.09. | Integrum AB: The board of Integrum appoints Scott Flora as acting CEO | 99 | GlobeNewswire (Europe) | Integrums CEO Rickard Brånemark has today agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO... ► Artikel lesen | |
| 15.09. | ESMO: Bayer hopes to expand Nubeqa's prostate cancer reach with chemo-free regimen | 2 | FiercePharma | ||
| 15.09. | MacroGenics, Inc.: MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 | 202 | GlobeNewswire (Europe) | Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing... ► Artikel lesen | |
| 15.09. | Replimune Group Inc: Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 | 124 | GlobeNewswire (Europe) | Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1... ► Artikel lesen | |
| 15.09. | Lantheus Holdings, Inc.: Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 | 147 | GlobeNewswire (Europe) | Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete... ► Artikel lesen | |
| 15.09. | 23andMe, Inc.: 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study | 134 | GlobeNewswire (Europe) | 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics... ► Artikel lesen | |
| 15.09. | 23andMe, Inc.: 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial | 81 | GlobeNewswire (Europe) | 23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and... ► Artikel lesen | |
| 15.09. | MAX Power Mining Corp. Announces Results of Annual General and Special Meeting | 339 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) ("MAX Power" or the "Company") announces the results of its annual general... ► Artikel lesen | |
| 15.09. | Platform Science to Acquire Trimble's Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology | 501 | PR Newswire | Partnership will Accelerate Global Expansion of Virtual Vehicle Trimble to Become a Shareholder in Platform Science's Expanded Business WESTMINSTER, Colo. and SAN DIEGO, Sept. 15, 2024 /PRNewswire/... ► Artikel lesen | |
| 15.09. | Akeso, Inc.: Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024 | 105 | PR Newswire | HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed... ► Artikel lesen | |
| 15.09. | Akeso, Inc.: Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 | 79 | PR Newswire | Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated
HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the... ► Artikel lesen | |
| 15.09. | Johnson & Johnson: New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer | 133 | PR Newswire | Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive
... ► Artikel lesen | |
| 15.09. | SABANA INDUSTRIAL REIT: GENERAL ANNOUNCEMENT::UPDATE ON THE STATUS OF THE EGM REQUISITION DATED 12 AUGUST 2024 | 3 | SGX Company Announcements | ||
| 15.09. | SARINE TECHNOLOGIES LTD.: SHARE BUY BACK - DAILY SHARE BUY-BACK NOTICE::DAILY SHARE BUY-BACK NOTICE 13 SEPTEMBER 2024 | 1 | SGX Company Announcements | ||
| 15.09. | SYNLAIT MILK LIMITED: Synlait executes documentation for new bank refinancing | - | ASX | ||
| 15.09. | SYNLAIT MILK LIMITED: Notification of Lapse of Performance Share Rights | - | ASX | ||
| 15.09. | AUCKLAND INTERNATIONAL AIRPORT LIMITED: AIA - announces $1.4 billion equity raise | - | ASX |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 7.372 |
| EVOTEC | 3.652 |
| SUPER MICRO COMPUTER | 2.729 |
| BAYER | 2.620 |
| NEL | 1.979 |
| MICROSTRATEGY | 1.358 |
| RHEINMETALL | 1.299 |
| TESLA | 1.145 |
| TUI | 1.096 |
| THYSSENKRUPP | 1.013 |
| PALANTIR TECHNOLOGIES | 957 |
| BIONTECH | 859 |
| PORSCHE AG | 801 |
| VOLKSWAGEN | 798 |
| RENK GROUP | 780 |
| COINBASE GLOBAL | 616 |
| AIXTRON SE | 608 |
| COMMERZBANK | 588 |
| DEUTSCHE BANK | 587 |
| GAMESTOP | 581 |
| BYD | 579 |
| JINKOSOLAR | 521 |
| AMAZON | 517 |
| BASF | 501 |
| MERCEDES-BENZ | 499 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
